Semler Scientific Inc

Semler Scientific — IPO Roadshow (February 2014)

34 slides from Semler Scientific's IPO roadshow presentation, Feb 7, 2014

  1. Slide 1: Corporate Presentation, January 2014

    1 January 2014 Corporate Presentation

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements 2 This presentation includes statements that are, or may be deemed, “forward - looking statements.” In some cases, these forward - lo oking statements can be identified by the use of forward - looking terminology, including the terms “believe”, “estimates,” “anticipates ,”

  3. Slide 3: Free Writing Prospectus Statement

    3 This presentation highlights basic information about us and the offering. Because it is a summary, it does not contain all o f t he information that you should consider before investing. We have filed a registration statement (including a preliminary prospectus) with the SEC for the offering to wh

  4. Slide 4: Initial Public Offering Summary

    4 Initial Public Offering Summary Shares Offered Over - Allotment Price Range Exchange / Ticker Use of Proceeds Sole Book - Runner 1,150,000 (100% Primary) 15% or 172,500 (100 % Primary ) $12.00 - $14.00 NASDAQ Capital Market / SMLR Working Capital and Other General Corporate Purposes Aegis Capital

  5. Slide 5: Experienced Management and Board

    5 • Herb Semler, MD – Founder/Chairman Founded Instromedix acquired by Alaris in 1998 for $60M and Advanced Vascular Dynamics acquired in 2005 • Doug Murphy - Chutorian – CEO Founded ESTI – IPO at market cap of $400M in 1996; Atlantis Catheter acquired by Biocompatibles in 1996 for $75M • Bob McRae

  6. Slide 6: Risk Assessment Diagnostics Industry

    6 • Help to identify the risk profile of patients • Allow providers to capture full payment for medical conditions that are ‘ codeable ’ • Codeable conditions increase revenue per patient • Prevention programs may be initiated • Healthcare costs may be decreased • Wellness and quality of care may be

  7. Slide 7: Payment Reform "Here to Stay"

    7 “ This is here to stay ,” said Dr. Sam Ho, chief medical officer at UnitedHealthcare. “ We are shifting from a volume - based payment model to value - based. The American health care system cannot afford to go back .” Payment Reform “Here to Stay” http://www.forbes.com/sites/brucejapsen/2013/07/10

  8. Slide 8: Fixed Payments Instead of Fee-For-Service

    Fixed Payments Instead of Fee - For - Service 8

  9. Slide 9: New Healthcare Paradigm

    9 • Fixed Payment is already in place for approximately 14 million Medicare Advantage patients • Trend towards Fixed Payment is increasing New Healthcare Paradigm

  10. Slide 10: Patients with Chronic Diseases Account for 75% of U.S. Healthcare Costs

    Patients with Chronic Diseases Account for 75% of U.S. Healthcare Costs 10 www.cdc.gov/chronicdisease/resources/publications/aag/chronic.htm www.cms.gov/research - statistics - data - and - systems/statistics - trends - and - reports/nationalhealthexpenddata/downloads/highlights.pdf www.cms.gov /res

  11. Slide 11: Combat the High Cost of Healthcare

    11 • Identify chronic disease or condition • Initiate high priority primary care • Prevent occurrence of events or progression of disease • Decrease healthcare costs • Increase wellness and quality of care Combat the High Cost of Healthcare Medical Risk Assessments

  12. Slide 12: Conditions Drive Payments - Initial Focus: Vascular Disease

    12 • Insurance plans and MDs may receive higher fees when conditions are identified • Find a specific condition and get a risk factor adjustment payment • Example: Vascular Disease pays 30% more List of Disease Conditions Conditions Drive Payments - Initial Focus: Vascular Disease http://www.cms.gov

  13. Slide 13: Initial Focus for Semler: Vascular Disease

    13 • Narrowing of blood vessels in the legs from atherosclerotic plaque • Often indicates plaque growth in the arteries of heart and neck as well • More than 80 million Americans are older than 50 years (U.S. Census). • 18 million may have vascular disease of the legs (Sage Group). • Patients with v

  14. Slide 14: Under-Diagnosed Condition

    14 “ Peripheral arterial disease (PAD) is the most common, deadly and costly cardiovascular disease that the public hasn’t heard of…” "When Achy Legs Are a Warning", The Informed Patient, Wall Street Journal, Nov 30, 2010 Under - Diagnosed Condition PAD is a form of vascular disease

  15. Slide 15: Identify Patients Now to Save Cost Later

    Identify Patients Now to Save Cost Later Medicare Advantage Patients 14 million Estimated 10% with Vascular Disease 1 1.4 million 30% Extra Payment (HCC 108*) $3,600 each Annual Incremental Fees $5.68 billion • Government is currently spending $164B to $290B to treat peripheral artery disease 2 • Ea

  16. Slide 16: Problems with the Traditional Test

    16 • Requires specially - trained technician • Not always accurate • Can be uncomfortable and time - consuming Problems with the Traditional Test The traditional test is an “ABI” or “Ankle - Brachial Index” ABI Test

  17. Slide 17: FloChec System: Simple, fast test

    17 Simple, fast test… FloChec™ System 17

  18. Slide 18: Measures blood flow difference between arms and legs

    18 …that measures blood flow difference between arms and legs… FloChec™ System 18

  19. Slide 19: Provides instant test results to the physician

    19 …and provides instant test results to the physician. FloChec™ System 19

  20. Slide 20: Fast and Practical in the Primary Care Office

    Fast and Practical in the Primary Care Office FloChec™ can be performed by a medical aide in less than four minutes, allowing the primary care practice to do these tests without a vascular technician or technologist. 20 4 Test Minute

  21. Slide 21: FloChec vs. Traditional ABI (Doppler)

    FloChec vs. Traditional ABI (Doppler) Technology Accuracy (95% CI) FloChec 0.87 (0.82, 0.92) Doppler 0.82 (0.76, 0.88) Technology Sensitivity (95% CI) FloChec 0.87 (0.79, 0.93) Doppler 0.78 (0.69, 0.85) Technology Specificity (95% CI) FloChec 0.88 (0.78, 0.94) Doppler 0.89 (0.79, 0.95) 0.6 0.7 0.8 0

  22. Slide 22: FloChec Can Pay for Itself in Less Than One Week

    22 FloChec ™ Can Pay for Itself in Less Than One Week Cost per test: $5 Assuming a frequency of undiscovered vascular disease: 10 – 20% Every 100 patients with newly - coded vascular disease could bring in: $300,000 annually Potential FloChec™ Return on Investment: 60 to 1 (first year alone) Hirsch

  23. Slide 23: Case Study: Customer ROI

    Case Study: Customer ROI • 10 clinics rent 10 FloChec™ units for >$40k annual rental fee total • ~ 500 patients with no known vascular disease are tested weekly with FloChec • 70 patients on average are found to have vascular disease and coded accordingly • Fixed payment per patient per year increas

  24. Slide 24: Potential Market & Call Points

    Potential Market & Call Points • Potential user base is about 250,000 primary care providers or about 100,000 FloChec™ units • Current market penetration is 1% • User base is aggregated under <2,000 insurance plans and provider groups that are the Semler call points • Monthly rentals are increasing

  25. Slide 25: Rental Business Model

    Rental Business Model • FloChec™ is a testing system with no disposable component • Monthly rental fee which we believe is reasonable for providers who receive fixed monthly payments per patient • So the Rental Model has an alignment of interest with the Fixed Payment Model 25 Other Features of Rent

  26. Slide 26: Operating Activities through September 2013

    26 • Launched product in the U.S. in 2011 • Revenue of $1.5M at 9 Months ended September 30, 2013 • 90% revenue growth rate (9 months 2013 compared to 9 months 2012) • 5 Direct Sales Reps and co - exclusive distributor • Contract manufacturing Operating Activities through September 2013

  27. Slide 27: Distribution Partner

    27 • Co - exclusive distribution with C.R. Bard, Inc. - $10B market cap company • Hundreds of sales reps introducing FloChec TM • Currently, <20% of revenue in 9 months ended September 30, 2013 Distribution Partner

  28. Slide 28: Growth Strategy – Product Expansion

    Growing Base of End - User Customers 28 Plans and Providers 2 nd Product 3 rd Product Growth Strategy – Product Expansion Heart Disease Cancer Neurologic Disease Lung Disease Bowel Disease Future Product Areas

  29. Slide 29: Patents and FDA Clearance

    29 • One patent issued with three additional U.S. patents pending • FDA cleared for commercial sale • Used every day routinely in medical practices across the nation Patents and FDA Clearance

  30. Slide 30: FloChec Installed User Base (units)

    FloChec™ Installed User Base (units) - 100 200 300 400 500 600 700 800 900 Mar-11 Jun-11 Sep-11 Dec-11 Mar-12 Jun-12 Sep-12 Dec-12 Mar-13 Jun-13 Sep-13 Total Base Total Base 30

  31. Slide 31: Financials

    31 Financials Income Statement Summary Nine Months ended 9/30/13 Nine Months ended 9/30/12 Revenue $ 1,493,000 $ 772,000 Cost of Revenue 276,000 232,000 Total Operating Expenses* 3,073,000 2,759,000 Net Loss $ (1,707,000) $ (2,085,000) Net Loss attributable to common stock $ (2.17) $ (1.77) Balance

  32. Slide 32: Capitalization Structure

    32 * assumes automatic conversion of preferred stock for an aggregate of 2,012,152 shares of common stock and cashless exercise of warrants to acquire 1,295,866 shares of preferred stock into 856,091 shares of common stock at an assumed IPO closing price of $13.00 per share (the midpoint of the pric

  33. Slide 33: Investment Summary

    33 • Healthcare payment reform is here now • Semler is positioned to benefit from healthcare reform • address the need for risk assessment products • deliver cost - effective wellness solutions for the care of patients with chronic diseases • provide economics that work for the providers, the insura

  34. Slide 34: Semler Scientific

    C Semler Scientific

Semler Scientific — IPO Roadshow (February 2014) on 6ix